Javascript must be enabled to continue!
Therapeutic management of gliosarcoma in the stupp protocol and temozolomide era
View through CrossRef
Background: The clinical management of primary gliosarcoma grade IV with curative intent is not entirely defined and the available data are limited, so the therapeutic management may be a challenge The application of the Stupp protocol may be the only effective treatment option. Case report: We report the case of a 57-year-old woman with a gliosarcoma of the left frontal lobe treated in a curative intent. She underwent craniotomy, followed by adjuvant radioterapy and 6 cycles of temozolomide, according to the Stupp protocol, resulting in complete response after 3.5 years from diagnosis. Conclusions: Gliosarcoma and glioblastoma are different histopathological entities and the use of the Stupp protocol, specifically studied for glioblastoma, is an off label application of the treatment protocol. Efforts should be focused in order to assess the efficacy of this treatment modality and then on the prognosis carried by gliosarcoma tumor type.
Title: Therapeutic management of gliosarcoma in the stupp protocol and temozolomide era
Description:
Background: The clinical management of primary gliosarcoma grade IV with curative intent is not entirely defined and the available data are limited, so the therapeutic management may be a challenge The application of the Stupp protocol may be the only effective treatment option.
Case report: We report the case of a 57-year-old woman with a gliosarcoma of the left frontal lobe treated in a curative intent.
She underwent craniotomy, followed by adjuvant radioterapy and 6 cycles of temozolomide, according to the Stupp protocol, resulting in complete response after 3.
5 years from diagnosis.
Conclusions: Gliosarcoma and glioblastoma are different histopathological entities and the use of the Stupp protocol, specifically studied for glioblastoma, is an off label application of the treatment protocol.
Efforts should be focused in order to assess the efficacy of this treatment modality and then on the prognosis carried by gliosarcoma tumor type.
Related Results
Clinical Insights and Management Strategies for Gliosarcoma: A Case Report
Clinical Insights and Management Strategies for Gliosarcoma: A Case Report
Abstract
Introduction: Gliosarcoma (GSM) is a rare, aggressive primary CNS tumor and a histopathological variant of glioblastoma, characterized by both glial and sarcomatou...
Synthesis, Characterization and Evaluation of Cadmium Sulfide Nanoparticles Capped with Dextrin and Functionalized with Temozolomide
Synthesis, Characterization and Evaluation of Cadmium Sulfide Nanoparticles Capped with Dextrin and Functionalized with Temozolomide
Nanoparticles are currently used as drug carriers. Temozolomide is an antineoplastic drug for tumor in central nervous system. It presents a half‐life of 1.8 hours. For this reason...
HIF-1α Inhibition Sensitized Pituitary Adenoma Cells to Temozolomide by Regulating Presenilin 1 Expression and Autophagy
HIF-1α Inhibition Sensitized Pituitary Adenoma Cells to Temozolomide by Regulating Presenilin 1 Expression and Autophagy
Pituitary adenomas usually develop temozolomide resistance, which could compromise the anticancer effects of temozolomide. Suppression of hypoxia-inducible factor 1α has been shown...
Role of temozolomide regimen on survival outcomes in molecularly stratified WHO Grade II gliomas: A systematic review
Role of temozolomide regimen on survival outcomes in molecularly stratified WHO Grade II gliomas: A systematic review
Objective/Introduction: Although a critical chemotherapeutic, temozolomide's optimal regimen for 2016 World Health Organization (WHO) Grade II gliomas remains elusive, hence there ...
Abstract 1249: SetD2 histone methyltransferase mutation status predicts treatment response in glioblastoma: Strategies to overcome chemoresistance
Abstract 1249: SetD2 histone methyltransferase mutation status predicts treatment response in glioblastoma: Strategies to overcome chemoresistance
Abstract
Purpose: Glioblastoma (GBM) is a highly aggressive primary brain tumor. A major challenge in GBM treatment is tumor resistance to radiation and chemotherapy...
the Irradiation of Two Cases of Gliosarcoma: Place and Modalities of Radiotherapy
the Irradiation of Two Cases of Gliosarcoma: Place and Modalities of Radiotherapy
Introduction: Gliosarcoma is a rare histopathologic variant of glioblastoma traditionally associated with a poor prognosis.We present two cases of Gliosarcoma treated in our depart...
P14.09 BORTEM-17: A Phase IB/II Single-Arm, Control Non-Randomized, Multicentre, Open Label Clinical Trial for Recurrent Glioblastoma with unmethylated MGMT promoter (NCT03643549)
P14.09 BORTEM-17: A Phase IB/II Single-Arm, Control Non-Randomized, Multicentre, Open Label Clinical Trial for Recurrent Glioblastoma with unmethylated MGMT promoter (NCT03643549)
Abstract
BACKGROUND
Glioblastoma (GBM) is the most malignant primary brain tumor in adults where median survival in unselected p...
CLRM-06 PROSPECTIVE CLINICAL STUDY OF CONVENTIONALLY FRACTIONATED CONCURRENT CHEMORADIOTHERAPY AND HYPOFRACTIONATED CONCURRENT CHEMORADIOTHERAPY AFTER THE SURGERY OF HIGH-GRADE GLIOMAS
CLRM-06 PROSPECTIVE CLINICAL STUDY OF CONVENTIONALLY FRACTIONATED CONCURRENT CHEMORADIOTHERAPY AND HYPOFRACTIONATED CONCURRENT CHEMORADIOTHERAPY AFTER THE SURGERY OF HIGH-GRADE GLIOMAS
Abstract
PURPOSE
To observe and evaluate the efficacy and safety of conventional fractionated concurrent chemoradiotherapy and h...

